Skip to main content
. Author manuscript; available in PMC: 2016 May 10.
Published in final edited form as: Cancer Gene Ther. 2013 Jul 5;20(8):437–444. doi: 10.1038/cgt.2013.38

Figure 1.

Figure 1

Inhibition of endothelial cell tube formation. HUVECs were treated with medium containing VEGF-A, RAMBO, and cilengitide, and then assayed by the KURABO Angiogenesis Kit. A: The representative images show tube formation of HUVECs. a: VEGF-A (10 ng/mL), b: VEGF-A + RAMBO (5×102 pfu), c: VEGF-A + cilengitide (0.1 μM), and d: VEGF-A+RAMBO (5.0 ×102 pfu) + cilengitide (0.1 μM).

B: Significant reduction in tube formation of HUVECs treated with RAMBO and cilengitide combined compared to RAMBO or cilengitide monotherapy (*: P = 0.0090 and **: P = 0.028, respectively).